Perseus Proteomics has been focusing on antibody drug discovery since its establishment in 2001, based on the cutting-edge technology of Research Center for Advanced Science and Technology of the University of Tokyo and the extensive research network. Antibodies, which are defensive function inherent to human bodies, fight with foreign objects including viruses and germs. Through the research on antibodies for more than 20 years, the Company has not only improved its technology on a conventional hybridoma method but also developed its own antibody technologies such as phage libraries with high variety and the screening method for their efficient utilization. By applying such technologies, the Company has been tackling development of innovative antibody drugs that meet unmet medical needs including cancers.
So far, the Company has licensed out 3 antibodies including RIT and ADC to pharmaceutical companies. It has succeeded in obtaining an innovative antibody which is expected to have a wide indication to blood cancers including acute myeloid leukemia (AML) and malignant lymphoma (ML) and is now proceeding with the first phase 1 clinical trial for the Company on polycythemia vera patients.
The technologies and research environment of therapeutic drugs are daily changing. The Company will contribute to the global healthcare by strengthening even closer collaboration with academia including pharmaceutical companies and universities, integrating sophisticated technologies constantly, and creating excellent new antibody drug seeds.
President & CEO